Morales Torres, Cristina https://orcid.org/0000-0002-7126-6565
Wu, Mary Y. https://orcid.org/0000-0002-2074-6171
Hobor, Sebastijan
Wainwright, Elanor N. https://orcid.org/0000-0001-6409-3881
Martin, Matthew J.
Patel, Harshil https://orcid.org/0000-0003-2707-7940
Grey, William https://orcid.org/0000-0001-8209-5645
Grönroos, Eva https://orcid.org/0000-0001-8303-5409
Howell, Steven
Carvalho, Joana
Snijders, Ambrosius P. https://orcid.org/0000-0002-5416-8592
Bustin, Michael https://orcid.org/0000-0002-5147-7242
Bonnet, Dominique https://orcid.org/0000-0002-4735-5226
Smith, Paul D. https://orcid.org/0000-0002-2812-5978
Swanton, Charles https://orcid.org/0000-0002-4299-3018
Howell, Michael https://orcid.org/0000-0003-0912-0079
Scaffidi, Paola https://orcid.org/0000-0002-3642-4193
Funding for this research was provided by:
Cancer Research UK (FC001152)
RCUK | Medical Research Council (FC001152)
Wellcome Trust (FC001152)
Article History
Received: 7 March 2019
Accepted: 19 March 2020
First Online: 14 April 2020
Competing interests
: M.J.M. and P.D.S. are employees of AstraZeneca, which developed the EGFRi osimertinib/Tagrisso. All other authors have no competing interests.